US EditionFDA Approves Treatment for Moderate-to-Severe Chronic Hand Eczema
Summary by Plastic Surgery Practice
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
FDA Approves Treatment for Moderate-to-Severe Chronic Hand Eczema
Regulatory approval is based on clinical trials showing improvements in symptom severity and treatment success at 16 weeks. LEO Pharma Inc announced that the US Food and Drug Administration (FDA) has approved Anzupgo (delgocitinib) cream for the topical treatment of moderate-to-severe chronic hand eczema in adults who have had an inadequate response to, or are not advised to use, topical corticosteroids. According to a release from the company, …
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
